Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pfizer’s Double Dose Of Good News: Caduet Combo, Spiriva Clear FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Caduet clears FDA for the "simultaneous treatment of high blood pressure and high cholesterol," Pfizer says. The Norvasc and Lipitor combination product could broaden Pfizer’s reach in the cholesterol market.

You may also be interested in...



Pfizer Expects To File 12 "Major" NDAs By The End Of 2006

The company's strategy to weather upcoming patent expirations includes plan to file 20 NDAs over the five-year period ending 2006, U.S. Pharmaceuticals President Pat Kelly tells investors.

Pfizer Expects To File 12 "Major" NDAs By The End Of 2006

The company's strategy to weather upcoming patent expirations includes plan to file 20 NDAs over the five-year period ending 2006, U.S. Pharmaceuticals President Pat Kelly tells investors.

Pfizer Caduet Requires Prior Authorization Under Massachusetts Medicaid

MassHealth is also requiring prior authorization for Amgen’s small molecule chronic kidney agent Sensipar and Lilly’s intramuscular formulation of the antipsychotic Zyprexa.

Related Content

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel